Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT00315380
Recruiting Observational

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

NCT00315380 · tracked via the Priya Life Science Germany tracker
Sponsor
University of Pennsylvania
Phase
Observational
Started
2006-04
Last updated
2026-08-28

Condition(s) studied

Eosinophilic Granulomatosis With PolyangiitisChurg-Strauss Syndrome

Study summary

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study. Parent or guardian willing to provide informed consent, if applicable Exclusion Criteria: \- Inability to give informed consent and to sign the consent form

Primary outcome measure(s)

  • Discover biomarkers in EGPA capable of measuring disease activity and response to treatment — Study completion

Trial sites (15)

FacilityCityRegionStatus
University of California San Diego San Diego California Completed
National Jewish Health Denver Colorado Completed
Brigham and Women's Hospital Boston Massachusetts Completed
Mayo Clinic Rochester Minnesota Completed
Cleveland Clinic Foundation Cleveland Ohio Completed
University of Pennsylvania Philadelphia Pennsylvania Completed
University of Pittsburgh Pittsburgh Pennsylvania Completed
University of Utah Salt Lake City Utah Completed
St. Joseph's Healthcare Hamilton Ontario Recruiting
Mount Sinai Hospital Toronto Ontario Completed
medius KLINIK KIRCHHEIM Kirchheim unter Teck Germany Recruiting
AOU Meyer IRCCS Florence Italy Recruiting
Cambridge University Hospitals Nhs Foundation Trust Cambridge United Kingdom Recruiting
Imperial College Healthcare NHS Trust/ Imperial College London London United Kingdom Recruiting
Guy'S and St Thomas' Nhs Foundation Trust London United Kingdom Recruiting

More University of Pennsylvania trials in Germany

Effects of Long-Duration Spaceflight on General and Spatial Cognition and Its Neural Basis Enrolling by invitation
PROSpect: Prone and Oscillation Pediatric Clinical Trial Active, not recruiting
Vascular MRI Evaluation in Giant Cell Arteritis (VEGA) Recruiting
Abatacept for the Treatment of Giant Cell Arteritis Recruiting

Other trials for the same condition

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Active, not recruiting
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00315380 on ClinicalTrials.gov ↗ ← All trials in Germany